We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+18.22%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$495M
AUM Growth
+$97.7M
Cap. Flow
+$53.3M
Cap. Flow %
10.77%
Top 10 Hldgs %
75.85%
Holding
33
New
7
Increased
3
Reduced
4
Closed
4

Top Buys

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$60M
2
KALA icon
KALA BIO
KALA
+$25.5M
3
VRNA
Verona Pharma
VRNA
+$10.4M
4
KDMN
Kadmon Holdings, Inc.
KDMN
+$9.52M
5
ZLAB icon
Zai Lab
ZLAB
+$9.06M

Top Sells

Rank Stock Value
1
CDXS icon
Codexis
CDXS
+$12.4M
2
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$5.32M
3
DVAX
Dynavax Technologies
DVAX
+$3.47M
4
AKTX
Akari Therapeutics
AKTX
+$855K
5
SBBP
Strongbridge Biopharma plc.
SBBP
+$258K

Sector Composition

Rank Sector Weight
1 Healthcare 92.89%
2 Materials 1.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
1
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$73.9M 14.93%
+1,976,818
New +$60M
ACRS icon
2
Aclaris Therapeutics
ACRS
$739M
$73.8M 14.91%
2,858,569
– –
ASND icon
3
Ascendis Pharma A/S
ASND
$16.3B
$64M 12.94%
1,766,832
– –
NBRV
4
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$33.4M 6.74%
16,297
+211
+1% +$495K
KALA icon
5
KALA BIO
KALA
$11.5M
$26.5M 5.35%
+464
New +$25.5M
VRNA
6
DELISTED
Verona Pharma
VRNA
$22.9M 4.63%
1,492,951
+788,726
+112% +$10.4M
SBBP
7
DELISTED
Strongbridge Biopharma plc.
SBBP
$20.4M 4.13%
2,962,645
-37,355
-1% -$258K
RNAC icon
8
Cartesian Therapeutics
RNAC
$225M
$20.4M 4.13%
37,306
– –
CDXS icon
9
Codexis
CDXS
$136M
$20.3M 4.11%
3,054,825
-2,240,000
-42% -$12.4M
EIGR
10
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$19.7M 3.97%
59,570
– –
AIMT
11
DELISTED
Aimmune Therapeutics
AIMT
$19.3M 3.89%
776,813
– –
AAAP
12
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$16.9M 3.41%
249,241
-109,545
-31% -$5.32M
KDMN
13
DELISTED
Kadmon Holdings, Inc.
KDMN
$11.2M 2.26%
+3,333,333
New +$9.52M
AMRS
14
DELISTED
Amyris Inc.
AMRS
$9.04M 1.83%
+2,826,711
New +$8.96M
ZLAB icon
15
Zai Lab
ZLAB
$2.11B
$8.78M 1.77%
+325,000
New +$9.06M
SLNO
16
DELISTED
Soleno Therapeutics
SLNO
$7.64M 1.54%
195,937
– –
AUPH icon
17
Aurinia Pharmaceuticals
AUPH
$1.92B
$7.61M 1.54%
1,213,290
+200,141
+20% +$1.26M
AGRX
18
DELISTED
Agile Therapeutics
AGRX
$6.75M 1.36%
757
– –
RGNX icon
19
Regenxbio
RGNX
$606M
$5.42M 1.09%
164,403
– –
FOMX
20
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$4.75M 0.96%
855,000
– –
TRVN
21
DELISTED
Trevena, Inc.
TRVN
$4.41M 0.89%
2,765
– –
TMBR
22
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$4.03M 0.81%
940
– –
SRRA
23
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$3.78M 0.76%
60,957
– –
CRSP icon
24
CRISPR Therapeutics
CRSP
$4.64B
$2.66M 0.54%
148,878
– –
RVNC
25
DELISTED
Revance Therapeutics, Inc.
RVNC
$2.13M 0.43%
77,373
– –
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
WC
Whitney & Co Rochester, New York $1.2B AUM 24.16% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
RCYC
Richard C. Young & Co Newport, Rhode Island $1.21B AUM 38.41% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Vivo Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Vivo Capital held 33 positions worth $495M, up 25% from $397M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Vivo Capital deployed $53.3M of net new capital in Q3 2017, opening 7 new positions and adding to 3 existing holdings. Its largest new stake was Biohaven Pharmaceutical Holding Company Ltd.: 1,976,818 shares worth $73.9M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 82% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was Codexis, an estimated $12.4M trimmed.

  • Vivo Capital's largest Q3 2017 buy was Biohaven Pharmaceutical Holding Company Ltd.: 1,976,818 shares worth $73.9M.
  • Vivo Capital added most to Verona Pharma in Q3 2017, an estimated $10.4M increase.
  • Vivo Capital's biggest Q3 2017 reduction was Codexis, cutting an estimated $12.4M.
  • Vivo Capital fully exited Dynavax Technologies in Q3 2017, selling an estimated $3.47M.
  • Vivo Capital's ten largest holdings make up 76% of its $495M portfolio in Q3 2017.
  • Vivo Capital opened 7 new positions and closed 4 in Q3 2017.
  • Vivo Capital's portfolio value rose 25% quarter-over-quarter to $495M.

Based on Vivo Capital's 13F filing for Q3 2017, filed 13 Nov 2017.